Dendritic cells against autoimmunity and in transplantat rejection
The invention is a preparation of dendritic cells producing the immunosuppressive protein IL-35Ig and exposing on their surface a specific peptide that activates specific T lymphocyte response. Thanks to selective inhibition of those T lymphocytes responsible for pathologic immune reactions, the invention can find application in autoimmunity, allergy and transplant rejection treatment.
The invention consists in preparing dendritic cells (DC) modified by IL-35Ig gene construct so that they become able to inhibit selectively an overwhelming, undesired and pathologic immune response. Selective action is guided by the antigen (peptide) presented by DC to T lymphocytes. In fact, IL-35Ig produced in the cell microenvironment exerts a tolerogenic action mainly on those T cells capable to recognize the peptide presented by DC, saving other immunocompetent cells. The innovation of this kind of negative vaccination resides in combining in the same cell, the DC, production of the strongly tolerogenic cytokine IL-35Ig and presentation of a specific peptide to be selectively targeted by immunosuppressive response in the treatment of autoimmunity, allergy and transplant rejection.
- Treatment of autoimmune deseases;
- Treatment of rejection in organ transplantation;
- Treatment of allergy.
- Local production of IL-35Ig, rather than exogenous administration of the protein;
- Selectivity in targeting T lymphocytes reactive against a pathogenetic peptide;
- Versatility (depending on the peptide presented by DCs, a specific and selective immunosuppression is achieved).